CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidence of targeted population in Malaysia
3.5.1.2.Increase in population of geriatric population in Malaysia
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.2.Restraints
3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies in Malaysia
3.5.2.2.Short half-life of radiopharmaceuticals
3.5.3.Opportunity
3.5.3.1.Use of radiopharmaceuticals in neurological applications
3.5.4.Impact analysis
3.6.COVID-19 Impact analysis on Malaysia nuclear medicines Market
3.7.Cost estimation & return of Investment (Roi) for establishing A 30MEV cyclotron facility
CHAPTER 4:MALAYSIA NUCLEAR MEDICINE MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Diagnostics
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.3.Therapeutics
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.4.Biochemistry research
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast
CHAPTER 5:MALAYSIA NUCLEAR MEDICINE MARKET, BY MODALITY
5.1.Overview
5.1.1.Market size and forecast
5.2.SPECT
5.2.1.Market size and forecast
5.3.PET
5.3.1.Market size and forecast
5.4.Beta emitters
5.4.1.Market size and forecast
5.5.Alpha emitters
5.5.1.Market size and forecast
5.6.Brachytherapy
5.6.1.Market size and forecast
5.7.Others
5.7.1.Market size and forecast
CHAPTER 6:MALAYSIA NUCLEAR MEDICINE MARKET, BY APPLICATION
6.1.Overview
6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast
6.2.Oncology
6.2.1.Market size and forecast
6.3.Cardiology
6.3.1.Market size and forecast
6.4.Thyroid
6.4.1.Market size and forecast
6.5.Neurology
6.5.1.Market size and forecast
6.6.Others
6.6.1.Market size and forecast
CHAPTER 7:MALAYSIA NUCLEAR MEDICINE MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospitals & diagnostic centers
7.2.1.Market size and forecast
7.3.Research Institutes
7.3.1.Market size and forecast
CHAPTER 8:COMPANY PROFILES
8.1.CARDINAL HEALTH, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.FUJIFILM HOLDINGS CORPORATION (IRVINE SCIENTIFIC SALES COMPANY, INC.)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments
8.3.GE HEALTHCARE
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.ION BEAM APPLICATIONS (ION BEAM APPLICATIONS, SA)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.LANTHEUS HOLDINGS, INC. (LANTHEUS MEDICAL IMAGING, INC.)
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.MERCK KGAA (SIGMA ALDRICH)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.NOVARTIS AG (ADVANCED ACCELERATOR APPLICATIONS S.A.)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.OTSUKA HOLDING CO., LTD. (ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.SIEMENS HEALTHCARE GmbH
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TAIYO NIPPON SANSO CORPORATION (MITSUBISHI CHEMICAL HOLDINGS CORP)
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
TABLE 01.COSTS OF ESTABLISHING A CYCLOTRON RADIOPHARMACEUTICAL PRODUCTION CENTRE
TABLE 02.MALAYSIA NUCLEAR MEDICINE MARKET, BY TYPE, 2020–2028($MILLION)
TABLE 03.MALAYSIA NUCLEAR MEDICINE MARKET, BY MODALITY, 2020–2028($MILLION)
TABLE 04.MALAYSIA NUCLEAR MEDICINE MARKET FOR SPECT, 2020–2028 ($MILLION)
TABLE 05.MALAYSIA NUCLEAR MEDICINE MARKET FOR PET, 2020–2028 ($MILLION)
TABLE 06.MALAYSIA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020–2028($MILLION)
TABLE 07.MALAYSIA NUCLEAR MEDICINE MARKET, BY END USER, 2020–2028($MILLION)
TABLE 08.CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 09.CARDINAL HEALTH: OPERATING SEGMENT
TABLE 10.CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 11.FUJIFILM: COMPANY SNAPSHOT
TABLE 12.FUJIFILM: OERATING SEGMENT
TABLE 13.FUJIFILM : PRODUCT PORTFOLIO
TABLE 14.GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 15.GE HEALTHCARE: OERATING SEGMENT
TABLE 16.GE HEALTHCARE : PRODUCT PORTFOLIO
TABLE 17.IBA: COMPANY SNAPSHOT
TABLE 18.IBA: OPERATING SEGMENT
TABLE 19.IBA: PRODUCT PORTFOLIO
TABLE 20.IBA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 21.LANTHEUS: COMPANY SNAPSHOT
TABLE 22.LANTHEUS: OPERATING SEGMENTS
TABLE 23.LANTHEUS: PRODUCT PORTFOLIO
TABLE 24.MERCK: COMPANY SNAPSHOT
TABLE 25.MERCK: OPERATING SEGMENTS
TABLE 26.MERCK: PRODUCT PORTFOLIO
TABLE 27.NOVARTIS: COMPANY SNAPSHOT
TABLE 28.NOVARTIS: OERATING SEGMENT
TABLE 29.NOVARTIS : PRODUCT PORTFOLIO
TABLE 30.OTSUKA: COMPANY SNAPSHOT
TABLE 31.OTSUKA: OERATING SEGMENT
TABLE 32.OTSUKA : PRODUCT PORTFOLIO
TABLE 33.SIEMENS: COMPANY SNAPSHOT
TABLE 34.SIEMENS: OPERATING SEGMENTS
TABLE 35.SIEMENS: PRODUCT PORTFOLIO
TABLE 36.NIPPON SANSO: COMPANY SNAPSHOT
TABLE 37.NIPPON SANSO: OPERATING SEGMENT
TABLE 38.NIPPON SANSO: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.MALAYSIA NUCLEAR MEDICINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.LOW THREAT OF SUBSTITUTES
FIGURE 09.LOW THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.MALAYSIA NUCLEAR MEDICINE MARKET FOR DIAGNOSTICS, 2020–2028 ($MILLION)
FIGURE 14.MALAYSIA NUCLEAR MEDICINE MARKET FOR THERAPEUTICS, 2020–2028 ($MILLION)
FIGURE 15.MALAYSIA NUCLEAR MEDICINE MARKET FOR BIOCHEMISTRY RESEARCH, 2020–2028 ($MILLION)
FIGURE 16.MALAYSIA NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, 2020–2028 ($MILLION)
FIGURE 17.MALAYSIA NUCLEAR MEDICINE MARKET FOR ALPHA EMITTERS, 2020–2028 ($MILLION)
FIGURE 18.MALAYSIA NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY, 2020–2028 ($MILLION)
FIGURE 19.MALAYSIA NUCLEAR MEDICINE MARKET FOR OTHERS, 2020–2028 ($MILLION)
FIGURE 20.MALAYSIA NUCLEAR MEDICINE MARKET, BY ONCOLOGY, 2020–2028 ($MILLION)
FIGURE 21.MALAYSIA NUCLEAR MEDICINE MARKET, BY CARDIOLOGY, 2020–2028 ($MILLION)
FIGURE 22.MALAYSIA NUCLEAR MEDICINE MARKET, BY THYROID, 2020–2028 ($MILLION)
FIGURE 23.MALAYSIA NUCLEAR MEDICINE MARKET, BY NEUROLOGY, 2020–2028 ($MILLION)
FIGURE 24.MALAYSIA NUCLEAR MEDICINE MARKET, BY OTHERS, 2020–2028 ($MILLION)
FIGURE 25.MALAYSIA NUCLEAR MEDICINE MARKET, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2020–2028 ($MILLION)
FIGURE 26.MALAYSIA NUCLEAR MEDICINE MARKET, BY RESEARCH INSTITUTES, 2020–2028 ($MILLION)
FIGURE 27.CARDINAL HEALTH: NET SALES, 2018-2020 ($MILLION)
FIGURE 28.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.GE HEALTHCARE: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32.GE HEALTHCARE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 33.IBA: NET SALES, 2018-2020 ($MILLION)
FIGURE 34.IBA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.LANTHEUS: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.LANTHEUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.OTSUKA: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.OTSUKA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 45.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 46.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 48.NIPPON SANSO: NET SALES, 2018-2020 ($MILLION)
FIGURE 49.NIPPON SANSO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.NIPPON SANSO: REVENUE SHARE BY REGION, 2020 (%)
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/